Copyright © Inderes 2011 - present. All rights reserved.
  • Seneste
  • Markeder
    • Aktieoversigt
    • Finanskalender
    • Udbyttekalender
    • Research
    • Artikler
  • InderesTV
  • Forum
  • Om os
    • Fulgte selskaber
    • Team

Investeringsskole

Lær om grundlæggende investering med guider og artikler skrevet af Inderes' aktieeksperter.

CSRD reporting from a stock picker’s perspective: Double materiality assessment
Artikel29.1.2025, 09.14 af
Karoliina Loikkanen

CSRD reporting from a stock picker’s perspective: Double materiality assessment

Double materiality assessment is a tricky term, but in practice it is the point in sustainability reporting where the most relevant issues for the stock picker should be identified.

What a stock picker should understand about the new mandatory corporate sustainability (CSRD) reports, part 1.
Artikel21.1.2025, 11.24 af
Karoliina Loikkanen

What a stock picker should understand about the new mandatory corporate sustainability (CSRD) reports, part 1.

CSRD reports, or sustainability reports, will be part of mandatory annual reporting in the future. The reporting as a whole is very complex, and the aim of this new series of articles is to explain the key aspects of CSRD reporting for stock pickers.

Drug development investment: Value creation through M&As and licensing agreements
Artikel19.12.2024, 11.07 af
Antti Siltanen

Drug development investment: Value creation through M&As and licensing agreements

The fourth part of our series of articles focusing on investing in Life Science companies deals with value creation in drug development companies through M&As and licensing agreements.

Faron PharmaceuticalsHerantis PharmaOrionModulight

Bliv en del af Inderes community

Gå ikke glip af noget - opret en konto og få alle de mulige fordele

Inderes konto
Følgere og notifikationer om fulgte virksomheder
Analytikerkommentarer og anbefalinger
Værktøj til at sammenligne aktier og andre populære værktøjer
Opret konto
Probabilities of success in drug development
Artikel26.9.2024, 13.26 af
Antti Siltanen

Probabilities of success in drug development

The second part of our series of articles focusing on the basics of investing in Life Science companies deals with the likelihood of successful drug development.

Faron PharmaceuticalsHerantis PharmaMendus
Clinical phases of drug development
Artikel10.9.2024, 05.42 af
Antti Siltanen

Clinical phases of drug development

We are starting a series of articles focusing on the basics of investing in Life Science companies. This first part of the series describes the clinical phases of drug development that most drug development companies have to go through before they can apply for marketing authorization and commercialize a drug.

Faron PharmaceuticalsHerantis PharmaOrionMendus
Find os på de sociale medier
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Tag kontakt
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • Om os
  • Vores team
  • Karriere
  • Inderes som en investering
  • Tjenester for børsnoterede virksomheder
Vores platform
  • FAQ
  • Servicevilkår
  • Privatlivspolitik
  • Disclaimer
Inderes’ ansvarsfraskrivelse kan findes her. Detaljeret information om hver aktie, der aktivt overvåges af Inderes og HC Andersen Capital, er tilgængelig på de virksomhedsspecifikke sider på Inderes' hjemmeside. © Inderes Oyj. All rights reserved.